FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2294848008> ?p ?o ?g. }

• W2294848008 endingPage "18484" @default.
• W2294848008 startingPage "18469" @default.
• W2294848008 abstract "// Swati Dhar 1, * , Avinash Kumar 1, * , Liangfen Zhang 1, 2 , Agnes M. Rimando 3 , Janice M. Lage 2 , Jack R. Lewin 2 , Azeddine Atfi 1, 4 , Xu Zhang 5 , Anait S. Levenson 1, 2, 6 1 Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA 2 Department of Pathology, University of Mississippi Medical Center, Jackson, MS, USA 3 United States Department of Agriculture, Agriculture Research Service, Natural Product Utilization Research Unit, University, MS, USA 4 Department of Biochemistry, University of Mississippi Medical Center, Jackson, MS, USA 5 Center of Biostatistics and Bioinformatics, University of Mississippi Medical Center, Jackson, MS, USA 6 Current affiliation: Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, USA * These authors contributed equally to this work Correspondence to: Anait S. Levenson, e-mail: alevenson@umc.edu , anait.levenson@liu.edu Keywords: pterostilbene, prostate cancer, chemoprevention, therapy, MTA1 Received: October 09, 2015      Accepted: January 29, 2016      Published: March 01, 2016 ABSTRACT Overexpression of the epigenetic modifier metastasis-associated protein 1 (MTA1) is associated with aggressive human prostate cancer. The purpose of this study was to determine MTA1- targeted chemopreventive and therapeutic efficacy of pterostilbene, a natural potent analog of resveratrol, in pre-clinical models of prostate cancer. Here, we show that high levels of MTA1 expression in Pten -loss prostate cooperate with key oncogenes, including c-Myc and Akt among others, to promote prostate cancer progression. Loss-of-function studies using human prostate cancer cells indicated direct involvement of MTA1 in inducing inflammation and epithelial-to-mesenchymal transition. Importantly, pharmacological inhibition of MTA1 by pterostilbene resulted in decreased proliferation and angiogenesis and increased apoptosis. This restrained prostatic intraepithelial neoplasia (PIN) formation in prostate-specific Pten heterozygous mice and reduced tumor development and progression in prostate-specific Pten -null mice. Our findings highlight MTA1 as a key upstream regulator of prostate tumorigenesis and cancer progression. More significantly, it offers pre-clinical proof for pterostilbene as a promising lead natural agent for MTA1-targeted chemopreventive and therapeutic strategy to curb prostate cancer." @default.
• W2294848008 created "2016-06-24" @default.
• W2294848008 creator A5002217495 @default.
• W2294848008 creator A5016571184 @default.
• W2294848008 creator A5018755451 @default.
• W2294848008 creator A5040506694 @default.
• W2294848008 creator A5053329940 @default.
• W2294848008 creator A5053853878 @default.
• W2294848008 creator A5059192590 @default.
• W2294848008 creator A5073568638 @default.
• W2294848008 creator A5073675083 @default.
• W2294848008 date "2016-03-01" @default.
• W2294848008 modified "2023-09-26" @default.
• W2294848008 title "Dietary pterostilbene is a novel MTA1-targeted chemopreventive and therapeutic agent in prostate cancer" @default.
• W2294848008 cites W1493975626 @default.
• W2294848008 cites W1525136518 @default.
• W2294848008 cites W1549404046 @default.
• W2294848008 cites W1911919368 @default.
• W2294848008 cites W1969964090 @default.
• W2294848008 cites W1974834178 @default.
• W2294848008 cites W1974989557 @default.
• W2294848008 cites W1980854517 @default.
• W2294848008 cites W1985837914 @default.
• W2294848008 cites W1986397853 @default.
• W2294848008 cites W1995466174 @default.
• W2294848008 cites W2001932191 @default.
• W2294848008 cites W2016169568 @default.
• W2294848008 cites W2017685050 @default.
• W2294848008 cites W2023411987 @default.
• W2294848008 cites W2024318677 @default.
• W2294848008 cites W2030537988 @default.
• W2294848008 cites W2032048206 @default.
• W2294848008 cites W2032737825 @default.
• W2294848008 cites W2033054833 @default.
• W2294848008 cites W2037345578 @default.
• W2294848008 cites W2037959305 @default.
• W2294848008 cites W2043880395 @default.
• W2294848008 cites W2045701552 @default.
• W2294848008 cites W2046234516 @default.
• W2294848008 cites W2050760453 @default.
• W2294848008 cites W2052675271 @default.
• W2294848008 cites W2055100889 @default.
• W2294848008 cites W2058039607 @default.
• W2294848008 cites W2059724367 @default.
• W2294848008 cites W2061257207 @default.
• W2294848008 cites W2062393705 @default.
• W2294848008 cites W2070061120 @default.
• W2294848008 cites W2074380974 @default.
• W2294848008 cites W2075403828 @default.
• W2294848008 cites W2079436286 @default.
• W2294848008 cites W2082410007 @default.
• W2294848008 cites W2085682228 @default.
• W2294848008 cites W2101446038 @default.
• W2294848008 cites W2102574640 @default.
• W2294848008 cites W2103413641 @default.
• W2294848008 cites W2105436320 @default.
• W2294848008 cites W2106119346 @default.
• W2294848008 cites W2107277218 @default.
• W2294848008 cites W2116021928 @default.
• W2294848008 cites W2116043987 @default.
• W2294848008 cites W2121244179 @default.
• W2294848008 cites W2121640179 @default.
• W2294848008 cites W2121836743 @default.
• W2294848008 cites W2126618982 @default.
• W2294848008 cites W2128453465 @default.
• W2294848008 cites W2132615462 @default.
• W2294848008 cites W2148655885 @default.
• W2294848008 cites W2150931597 @default.
• W2294848008 cites W2152153043 @default.
• W2294848008 cites W2153188352 @default.
• W2294848008 cites W2157335263 @default.
• W2294848008 cites W2158626602 @default.
• W2294848008 cites W2159354629 @default.
• W2294848008 cites W2167105480 @default.
• W2294848008 cites W2192080449 @default.
• W2294848008 cites W2253959633 @default.
• W2294848008 cites W2602035017 @default.
• W2294848008 cites W30756126 @default.
• W2294848008 cites W4233973967 @default.
• W2294848008 cites W71502233 @default.
• W2294848008 doi "https://doi.org/10.18632/oncotarget.7841" @default.
• W2294848008 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4951302" @default.
• W2294848008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26943043" @default.
• W2294848008 hasPublicationYear "2016" @default.
• W2294848008 type Work @default.
• W2294848008 sameAs 2294848008 @default.
• W2294848008 citedByCount "50" @default.
• W2294848008 countsByYear W22948480082016 @default.
• W2294848008 countsByYear W22948480082017 @default.
• W2294848008 countsByYear W22948480082018 @default.
• W2294848008 countsByYear W22948480082019 @default.
• W2294848008 countsByYear W22948480082020 @default.
• W2294848008 countsByYear W22948480082021 @default.
• W2294848008 countsByYear W22948480082022 @default.
• W2294848008 countsByYear W22948480082023 @default.
• W2294848008 crossrefType "journal-article" @default.
• W2294848008 hasAuthorship W2294848008A5002217495 @default.
• W2294848008 hasAuthorship W2294848008A5016571184 @default.

• next